← Back to CORE30
COMPANY RESEARCH

LLY

LLY · CORE30 Company
CORE30 Rank #5
OVERALL SCORE92.5Rank #5 · Out of 100

Company research profile within the AtechFuture CORE30 universe.

QUALITY90.0

Capital efficiency, operating profitability and free cash flow.

GROWTH100.0

Revenue, EBITDA and free cash flow growth.

MOAT90.0

Network, customer lock-in and structural advantages.

01 / FINANCIAL FUNDAMENTALS

Financial Fundamentals

QUALITY · 90.0 / 100

ROIC

41.4%

Operating Margin

51.3%

FCF Margin

13.5%
QUALITY & GROWTH

Growth Performance

GROWTH · 100.0 / 100

Revenue CAGR 3Y

39.2%

EBITDA CAGR 3Y

71.4%

FCF CAGR 3Y

52.6%
02 / COMPETITIVE ADVANTAGES

Competitive Advantages

MOAT SUMMARY

Eli Lilly has built a comprehensive competitive moat through long-term R&D capabilities, clinical development expertise, patent protection, and global commercialization infrastructure. Key factors to watch include the market performance of Mounjaro and Zepbound, next-generation drug development, and global manufacturing capacity.

MOAT SCORE · 90.0 / 100

Network & Ecosystem

83.0 / 100

Customer & Technology Lock-in

91.0 / 100

Structural Advantage

96.0 / 100
03 / RESEARCH TIMELINE

Research Timeline

Material Business Events

Retatrutide Phase 3 TRIUMPH-1 and TRIUMPH-4 results and Taltz-Zepbound Phase 3b TOGETHER-PsA data announced

Why It Matters

Positive clinical evidence may expand the addressable market and strengthen the future product pipeline.

Our Research Assessment

The findings are positive pipeline evidence, especially for potential expansion of retatrutide into knee osteoarthritis and integrated immunometabolic treatment. However, the release is a summary rather than a complete clinical report; retatrutide remains investigational. No score change is justified yet.

Research Conclusion Changes

No material research conclusion changes recorded.